UBS lowered the firm’s price target on BioNTech to $101 from $110 and keeps a Neutral rating on the shares. The firm thinks the near-term focus for shares remains on Covid sales and increasing spend and while UBS sees potential upside from BioNTech’s pipeline longer term, thinks oncology opportunities may take a longer time to play out, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $90 from $99 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- BioNTech price target lowered to $90 from $115 at HSBC
- BioNTech price target lowered to $146 from $159 at BofA
- Biontech’s Bold AI Leap: Navigating Risks and Competition in the Tech Integration Era
